BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21132477)

  • 1. Palonosetron-induced migraine-type headache.
    Jain A
    Can J Anaesth; 2011 Feb; 58(2):230-1. PubMed ID: 21132477
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
    Singh PM; Borle A; Gouda D; Makkar JK; Arora MK; Trikha A; Sinha A; Goudra B
    J Clin Anesth; 2016 Nov; 34():459-82. PubMed ID: 27687434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palonosetron. RS 25259, RS 25259 197.
    Drugs R D; 1999 Oct; 2(4):251-2. PubMed ID: 10659403
    [No Abstract]   [Full Text] [Related]  

  • 4. Prolonged drug-induced myoclonus: is it related to palonosetron?
    Chaw SH; Chan L; Lee PK; Bakar JA; Rasiah R; Foo LL
    J Anesth; 2016 Dec; 30(6):1063-1066. PubMed ID: 27510560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ondansetron-induced migraine-type headache.
    Singh V; Sinha A; Prakash N
    Can J Anaesth; 2010 Sep; 57(9):872-3. PubMed ID: 20661681
    [No Abstract]   [Full Text] [Related]  

  • 7. Palonosetron induced anaphylaxis in an adult female.
    Gupta YK; Shanmugam SP; Padhy BM; Goyal A
    Br J Clin Pharmacol; 2010 Jul; 70(1):149-50. PubMed ID: 20642559
    [No Abstract]   [Full Text] [Related]  

  • 8. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period.
    Kovac AL; Eberhart L; Kotarski J; Clerici G; Apfel C;
    Anesth Analg; 2008 Aug; 107(2):439-44. PubMed ID: 18633021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial.
    Chun HR; Jeon IS; Park SY; Lee SJ; Kang SH; Kim SI
    Br J Anaesth; 2014 Mar; 112(3):485-90. PubMed ID: 24154700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM
    Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurokinin-1 and novel serotonin antagonists for postoperative and postdischarge nausea and vomiting.
    George E; Hornuss C; Apfel CC
    Curr Opin Anaesthesiol; 2010 Dec; 23(6):714-21. PubMed ID: 20871394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. We're tired of waiting.
    Lichtor JL; Glass PS
    Anesth Analg; 2008 Aug; 107(2):353-5. PubMed ID: 18633005
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a prospective, randomized, double-blind study.
    Moon YE; Joo J; Kim JE; Lee Y
    Br J Anaesth; 2012 Mar; 108(3):417-22. PubMed ID: 22277663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of palonosetron on the QTc interval in patients undergoing sevoflurane anaesthesia.
    Kim HJ; Lee HC; Jung YS; Lee J; Min JJ; Hong DM; Choi EK; Oh S; Jeon Y
    Br J Anaesth; 2014 Mar; 112(3):460-8. PubMed ID: 24129597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
    Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
    Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting serotonin antagonist (Palonosetron) and the NK-1 receptor antagonists: does extended duration of action improve efficacy?
    Melton MS; Nielsen KC; Tucker M; Klein SM; Gan TJ
    Anesthesiol Clin; 2014 Jun; 32(2):505-16. PubMed ID: 24882134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting.
    Candiotti KA; Kovac AL; Melson TI; Clerici G; Joo Gan T;
    Anesth Analg; 2008 Aug; 107(2):445-51. PubMed ID: 18633022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of palonosetron on postoperative nausea and vomiting in children following dental rehabilitation under general anesthesia.
    Yildirim MD; Cantekin K
    Pediatr Dent; 2014; 36(1):7E-11E. PubMed ID: 24717698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.